Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT for Gastro-Intestinal Acute Graft Versus Host Disease
NCT04059757Phase 2Withdrawn
- Start
- May 2022
- Primary completion
- Jun 2023
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of allogeneic fecal microbiota in Acute Graft-Versus-Host Disease (aGvHD). Primary endpoints: Number of participants experiencing toxicity at 6 months and Efficacy of FMT therapy as defined as number of responses at 28 days. Planned start May 2022; status: withdrawn.
02
Drugs
allogeneic fecal microbiota
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT04059757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04059757.